Tuesday, February 26, 2019
Mallinckrodt plc, the world's leading pharmaceutical specialty company, today announced that it has signed a research collaboration agreement with Transimmune AG, a company that develops novel immunotherapies based on its unique understanding of the physiological processes underlying the activation of host-presenting cells. antigen. Both companies will collaborate in transfer investigations to further expand the understanding of the underlying mechanism of action (MOA) of extracorporeal photopheresis and its application in the development of possible next-generation photopheresis technologies, with plans to expand the current photopheresis platform THERAKOS ™ by Mallinckrodt through new clinical trials.
In addition to improving the understanding of the MOA and making advances in the technological platform, it is expected that the knowledge obtained through this joint research with the experts of Transimmune expand the possible field of application in various immunomediated diseases. If there are clinical signs, these diseases may include cutaneous T-cell lymphoma (CTCL), graft-versus-host disease (GvHD), rejection of organ transplants, and all autoimmune diseases-whose exclusive authorization belongs to Mallinckrodt as stipulated in the agreement. -
The founder of Transimmune is Dr. Richard Edelson , professor of the Lerner chair of Dermatology, president and professor of the department of Dermatology of the Faculty of Medicine of Yale University and pioneer in photoapheresis. Dr. Edelson has spent decades studying the mechanism of action of photoapheresis and founded Transimmune to translate these discoveries into improvements in photoapheresis treatments.
" Mallinckrodt invests in assets and technologies to promote its application in disorders with limited treatment options and in the treatment of unattended patients with serious disorders," said Dr. Steven Romano , Executive Vice President and Chief Scientific Officer of Mallinckrodt . "This agreement is an example of our collaboration and partnership model with experts in clinical and basic research - similar to the recent collaborative research partnership announced with the Washington University School of Medicine in St. Louis - to expand our access to innovative science and technology in areas of mutual interest. "
Mallinckrodt and Transimmune will establish a joint steering committee that will consist of representatives of both companies that will supervise, review and coordinate the activities established in the agreement.
The intention of the companies is to explore a joint commercial collaboration agreement in relation to a next generation Mallinckrodt photopheresis system . Mallinckrodt is the only supplier of an integrated closed-loop photopheresis treatment, which is administered through its state-of-the-art photo-therapy system THERAKOS ™ CELLEX ™.